ALC vs TARS
Alcon Inc vs Tarsus Pharmaceuticals, Inc. — AI-powered side-by-side comparison
VS
TARS
Tarsus Pharmaceuticals, Inc.
63
Buy
| Metric | ALC | TARS |
|---|
| AI Score |
68
|
63
|
| Price |
$75.39
|
$69.50
|
| P/E Ratio |
45.39×
|
-63.72×
|
| ROE |
4.4%
|
-19.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
54.9%
|
90.6%
|
| Debt / Equity |
0.24×
|
0.26×
|
| Dividend Yield |
0.5%
|
0.0%
|
| RSI (14) |
73.4
|
80.7
|
| Beta |
0.703
|
0.512
|
| Expected Upside |
+11.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALC versus TARS.
ALC leads by 5 points.
ALC scores 68/100 (Buy) versus TARS at 63/100 (Buy).
ALC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 73 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 73 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
TARS Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 105.2% YoY -- genuine top-line momentum — Growth
- MACD histogram positive -- bullish momentum — Technical
- Low leverage (debt-to-equity 0.21) -- balance sheet can absorb a shock — Risk
Bear Case
- Price-to-book of 10.1x prices in significant intangible value — Value
- ROE of only -13.5% -- cheap may mean cheap for a reason — Value
- RSI at 81 is in overbought territory — Technical